Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Dermatophagoides Pteronyssinus.

NCT01564017 is registered in ClinicalTrials.gov with Roxall Medicina España S.A as lead sponsor.

NCT NCT01564017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01564017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Dermatophagoides Pteronyssinus.
Lead sponsor
Roxall Medicina España S.A
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
May 31, 2013
Enrollment
150 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinoconjunctivitis